The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

PRIORITY PRESS - 12th Milan Breast Cancer Conference

The ATAC Trial: 10-year Analysis

Milan, Italy / June 16-18, 2010

Milan - Studies have now established the efficacy of adjuvant third-generation aromatase inhibition over the antiestrogen tamoxifen in reducing the risk of breast cancer recurrence among postmenopausal women with hormone receptor-positive...

PRIORITY PRESS - 15th Congress of the European Hematology Association

Novel Agents Significantly Improve Outcomes in Multiple Myeloma

Barcelona, Spain / June 10-13, 2010

Barcelona - Novel agents, including a proteasome inhibitor and two immunomodulatory drugs, are changing the therapeutic landscape for multiple myeloma. Unlike in the past, the goal of treatment today is to attain complete remission....

MEDI-NEWS - Based on: Mateos et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28(13):2259-66.

Emerging Standard for Previously Untreated Multiple Myeloma Patients

June 2010

The standard first-line regimen for symptomatic multiple myeloma patients ineligible for high-dose chemotherapy preserves its survival advantage over the previous standard even when patients are followed across subsequent rescue regimens,...

MEDICAL FRONTIERS - 46th Annual Meeting of the American Society of Clinical Oncology

Update on Optimal Long-term Control of GIST with Targeted Therapies

Chicago, Illinois / June 4-8, 2010

Chicago - The efficacy of imatinib, an oral small molecule inhibitor in the long-term control of metastatic or unresectable gastrointestinal stromal tumours (GIST), has provided an impressive demonstration of the potency of targeted...

PRIORITY PRESS - 46th Annual Meeting of the American Society of Clinical Oncology

Enhancing Quality of Life for Metastatic Breast Cancer Patients

Chicago, Illinois / June 4-8, 2010

Chicago - New phase III comparative data have provided evidence for a rational first-line selection of a single-agent cytotoxic drug in the treatment of HER2-negative metastatic breast cancer (MBC). In guidelines such as those issued by the...

PRIORITY PRESS - 105th Annual Meeting of the American Urological Association

GnRH Antagonists: Advances in Androgen Deprivation Therapy for Prostate Cancer

San Francisco, California / May 29-June 3, 2010

San Francisco - GnRH agonists effectively suppress testosterone in over 90% of patients with advanced prostate cancer but can require as much as 30 days to achieve full suppressive effects, during which time testosterone levels actually...

PRIORITY PRESS - 25th Congress of the European Association of Urology

Androgen Deprivation Therapy in Prostate Cancer

Barcelona, Spain / April 16-20, 2010

Barcelona - New data have reinforced the utility of a gonadotropin-releasing hormone (GnRH) receptor blocker for slowing progression of advanced prostate cancer. Following a previous phase III study in which this agent compared favourably...

PRIORITY PRESS - 36th Annual Meeting of the European Group for Blood and Bone Marrow Transplantation (EBMT)

New Antifungal Strategies in High-risk Stem Cell Transplant Recipients

Vienna, Austria / March 21-24, 2010

Vienna - Although Candida infection is still probably the most widespread fungal infection in a surgical setting, Aspergillus and other mold pathogens are a substantial cause of morbidity and mortality in immunosuppressed patients. In...

PRIORITY PRESS - 36th Annual Meeting of the European Group for Blood and Bone Marrow Transplantation (EBMT)

Progress in Infection Management of Allogeneic Stem Cell Recipients

Vienna, Austria / March 21-24, 2010

Vienna - In the last 10 years, widespread use of allogeneic hematopoietic stem cell transplantation has decreased the risk of recurrence in patients with aggressive hematological malignancies. However, the associated conditioning and...

PAGE 8 OF 23   1 2 3 4 5 6 7 8 9 10 ...